In addition, the agent 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A), an α7 nAChR partial agonist, ameliorates negative symptoms in patients with schizophrenia [175], and Encenicline (EVP-6124), an α7 nAChR partial agonist and serotonergic 5-HT3 antagonist (5-hydroxytryptamine), showed promising results in preclinical testing and phase 1 and 2 clinical trials [176]. The gene discussed is CHRNA7; the disease is schizophrenia.